A Single-arm Exploratory Clinical Study of Anlotinib Hydrochloride Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients Who Have Progressed After Targeted Therapy and Chemotherapy
Latest Information Update: 07 Nov 2022
At a glance
- Drugs Catequentinib (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Nov 2020 Status changed from not yet recruiting to recruiting.
- 10 Nov 2020 New trial record